HLA class II-restricted T cell epitopes in public neoantigens of ESR1 and PIK3CA in breast cancer
Mutations in ESR1 and PIK3CA were recognized by CD4 + T cells from healthy donors through potential restriction by common HLA II alleles. Further studies are warranted to elucidate the landscape of HLA II presentation and validate the clinical applicability of these mutations for the immunotherapy of patients with endocrine-resistant breast cancer.
Authors
- Yukio Ando (ORCID: https://orcid.org/0000-0001-7115-9105)
- Hiroko Bando (ORCID: https://orcid.org/0000-0002-7361-3647)
- Hiroko Miyadera (ORCID: https://orcid.org/0000-0002-6805-414X)
- Sachie Hashimoto (ORCID: https://orcid.org/0000-0001-5973-9051)
- Hisato Hara (ORCID: https://orcid.org/0000-0002-2764-0353)
- Emiko Noguchi
Institutions
- University of Tsukuba (JP)
Publication Details
- Journal
- BMC Cancer
- Published
- 2025-04-04
- DOI
- https://doi.org/10.1186/s12885-025-13992-6
- Citations
- 2
- Primary Topic
- Immunotherapy and Immune Responses
- Type
- article
- Field-Weighted Citation Impact
- 1.59
Funders
- National Institutes of Health
- Japan Society for the Promotion of Science
- RIKEN